Condition : Ankylosing Spondylitis Intervention : Sponsor : Merck Active, not recruiting - verified November 2013

Condition : Rheumatoid Arthritis Intervention : Sponsors : Abbott; Institute of Political Economical & Social Researches, Greece Completed - verified August 2011

PsA patients receiving adalimumab are evaluated in a prospective, non-interventional study (NIS) for 2 years. Patients receive adalimumab 40 mg every other week (eow), per its label. Efficacy and safe...

Condition : Rheumatoid Arthritis Intervention : Biological: adalimumab (Humira) Sponsor : Abbott Recruiting - verified May 2011

Condition : Rheumatoid Arthritis Intervention : Sponsors : Abbott; Institute of Political Economical & Social Researches, Greece Completed - verified August 2011

PsA patients receiving adalimumab are evaluated in a prospective, non-interventional study (NIS) for 2 years. Patients receive adalimumab 40 mg every other week (eow), per its label. Efficacy and safe...

Condition : Rheumatoid Arthritis Intervention : Sponsor : Abbott Active, not recruiting - verified August 2011

Condition : Arthritis, Rheumatoid Interventions : Drug: Otelixizumab; Drug: Matching placebo Sponsor : GlaxoSmithKline Terminated - verified November 2013

Condition : Rheumatoid Arthritis Intervention : Sponsor : Abbott Completed - verified July 2011

Condition : Arthritis, Psoriatic Interventions : Drug: placebo; Drug: ustekinumab; Drug: ustekinumab; Drug: placebo; Drug: placebo; Drug: ustekinumab; Drug: ustekinumab; Drug: ustekinumab Sponsor : Ce...